Financial Performance - BioNTech reported a narrower second-quarter per-share loss of $1.82 (1.60 euros), compared to a loss of 3.36 euros a year ago, beating the consensus loss estimate of $2.42 per share [1] - The company achieved sales of $295.69 million (260.8 million euros), significantly higher than the 128.7 million euros reported a year ago and exceeding the consensus estimate of $147.90 million [1] Future Guidance - BioNTech reaffirmed its fiscal year 2025 revenue guidance of 1.7 billion to 2.2 billion euros, compared to the consensus estimate of 2.05 billion euros, with revenue expected to be concentrated in the last three to four months of the fiscal year [2] Strategic Developments - The CEO of BioNTech, Ugur Sahin, stated that the company is advancing towards becoming a multiproduct biotechnology company by strengthening its oncology strategy [2] Stock Performance - Following the earnings announcement, BioNTech shares increased by 0.9%, trading at $111.05 [2] Analyst Ratings - B of A Securities analyst Tazeen Ahmad maintained a Buy rating on BioNTech and raised the price target from $126 to $134 [5] - Wells Fargo analyst Mohit Bansal maintained an Overweight rating but lowered the price target from $170 to $150 [5]